MedLumics
Manufacturing · Spain · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Núcleo 3 2ºa 10-11, Tres Cantos, Madrid,...Phone Number
+34 918033925Website
www.medlumics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About MedLumics
MedLumics SL, founded in Madrid in 2011, is a medical device company focused on the design and development of an optically guided radio-frequency ablation system for the treatment of Atrial Fibrillation. Its flagship product, AblaView®, allows the operator to directly assess both the positioning of the ablation catheter on the myocardium and the continuity and transmurality of the ablation.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MedLumics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if MedLumics is spiking on competitors!
MedLumics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once MedLumics has new funding data
Click to see if MedLumics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at MedLumics
Check if MedLumics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on MedLumics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when MedLumics launches new products
Recommended Actions
Find VP level buyers at MedLumics
Find 2 more new buyers
Company Profile Activity
Activity Insights
MedLumics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MedLumics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MedLumics.
MedLumics financials insights
Gather financial insights about MedLumics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$4.7M
2017
Series B
$36.9M
2021
Other Financing Round
$21.7M
MedLumics Tech Stack
A closer look at the technologies used by MedLumics
See more technologies
MedLumics News & Media
MedLumics® Announces the Publication of FIM Results for the AblaView® (PF) Ablation System in (AF) Patients, Including Clinical Safety and Our Ability to Predict Durable Lesions at 3 Months With 100% Specificity
MADRID--(BUSINESS WIRE)--“We would like to thank the investigation site team and particularly the investigators and proctors in this groundbreaking first-in human trial and for enabling the publication of these important validating results.” Peter Hinchliffe, CEO MedLumics “Join us as we raise our Series B funding of €15m to reach our regulatory clinical trial readiness milestone. We are ready to move forward with these results toward treating the 100 million Atrial Fibrillation patients globalMedLumics is Proud to Announce the Completion of the FIM Study, With Successful Remapping at 3 Months, Demonstrating the Efficacy of the AblaView® Optically Guided Pulsed Field Ablation (PFA) System and Presentation at the AF Symposium 2025
MADRID--(BUSINESS WIRE)--MedLumics is proud to announce the completion of the FIM study, with successful remapping at 3 months, demonstrating the efficacy of the AblaView®MedLumics New CEO and Board Member Announces 10 Patients Treated in First in Man (FIM) Clinical Trial With the Real-Time Visually Guided AblaView PFA System
MADRID--(BUSINESS WIRE)--MedLumics, a medical device company developing fiber optically guided platform technologies for the treatment, initially, of Atrial fibrillation (AF), announced today 10 patients treated in the company’s First in Man clinical trial. The AblaView Unipolar Pulsed Field (PF) Ablation System, used in this trial, features MedLumics unique, real-time, fiber optic, visually guided AF ablation technology. MedLumics officially enters the clinical development phase with its AblaVMedLumics closes upsized EUR 18M (21.7M USD) financing round and appoints new Chairman
MADRID, Feb. 10, 2021 /PRNewswire/ -- MedLumics, a privately held medical device company developing AblaView®, the first optically-guided real-time ablation catheter system for the treatment of Atrial Fibrillation (AF), announced today that it has closed an upsized EUR 18 million (USD...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MedLumics
Sign Up For FreeTo access detailed company insights
MedLumics SL, founded in Madrid in 2011, is a medical device company focused on the design and development of an optically guided radio-frequency ablation system for the treatment of Atrial Fibrillation. Its flagship product, AblaView®, allows the operator to directly assess both the positioning of the ablation catheter on the myocardium and the co... Read More
